| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Factor VIII Inhibitor Evaluation, Plasma
MessageSendouts, Mayo test code: 8INHE
Test Code
LAB1238134
Alias/See Also
8INHE
Factor 8 Inhibitor Profile
Factor 8 Inhibitor Profile
CPT Codes
85240, 85390
Preferred Specimen
3 mL in 3 plastic vials, each containing 1 mL
Patient Preparation
1. Patient must not be receiving Coumadin (warfarin) or heparin therapy 2. Fasting preferred
Minimum Volume
2 Plastic vials, each containing 1 mL
Instructions
1. Specimen must be collected prior to factor replacement therapy.
2. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
3. Aliquot plasma (1-2 mL per aliquot) into 3 separate plastic vials, leaving 0.25 mL in the bottom of centrifuged vial.
4. Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or, ideally, at -40 degrees C or below.
2. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
3. Aliquot plasma (1-2 mL per aliquot) into 3 separate plastic vials, leaving 0.25 mL in the bottom of centrifuged vial.
4. Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or, ideally, at -40 degrees C or below.
Transport Container
Aliquot tube
Transport Temperature
Frozen
Specimen Stability
Frozen: 14 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject
Gross lipemia Reject
Gross icterus Reject
Methodology
Optical Clot-Based
FDA Status
Approved
Setup Schedule
Monday through Friday
Report Available
1 to 3 days
Limitations
Occasionally, a potent lupus-like anticoagulant may cause false-positive results for a specific factor inhibitor (eg, factor VIII or IX).
Reference Range
FACTOR VIII ACTIVITY ASSAY
Adults: 55-200%
Normal, full-term newborn infants or healthy premature infants typically have levels greater or equal to 40%.*
Adults: 55-200%
Normal, full-term newborn infants or healthy premature infants typically have levels greater or equal to 40%.*
Clinical Significance
Detecting the presence and titer of a specific factor inhibitor directed against coagulation factor VIII
This test is not useful for the detection of a lupus-like circulating anticoagulant inhibitor, a nonspecific circulating anticoagulant, or other inhibitors that are not specific for coagulation factors.
This test is not useful for the detection of a lupus-like circulating anticoagulant inhibitor, a nonspecific circulating anticoagulant, or other inhibitors that are not specific for coagulation factors.
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Factor VIII Inhibitor Evaluation, Plasma
